RxDoctor Payments DataLook up a doctor →

Annis Marney, MD

Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1437206315

Payments from drug & device makers

$26,024in general payments, 2019–2025

Across 1,403 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Lilly USA, LLC$3K
  • Abbott$2K
  • Amgen$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk202$3,500
Lilly USA, LLC167$3,084
Abbott115$2,230
Amgen(2 entities)120$2,143
AstraZeneca(2 entities)66$1,272
Boehringer Ingelheim60$1,039
Corcept Therapeutics49$930
Insulet Corporation51$895
Xeris Pharmaceuticals, Inc.42$861
Sanofi-aventis U.S. LLC54$855
Mannkind Corporation62$679
BETA Bionics, Inc.23$659
IBSA Pharma Inc.35$621
Cequr Corporation3$509
Medtronic(2 entities)26$497
AbbVie29$456
Dexcom, Inc.22$418
Ultragenyx Pharmaceutical Inc.16$359
Tandem Diabetes Care, Inc.16$358
Pfizer19$323
Ascensia Diabetes Care US Inc.7$270
Merck18$250
Radius Health, Inc.15$242
Chiesi USA, Inc.6$226
Valeritas, Inc.7$222
Bayer12$211
Zealand Pharma US, Inc.11$208
Averitas Pharma Inc.5$176
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$173
Sequel Med Tech, LLC8$164
Esperion Therapeutics, Inc.9$154
Neurocrine Biosciences, Inc.5$151
Ascendis Pharma Endocrinology Inc7$148
Shire North American Group Inc11$146
Novartis7$114
Kyowa Kirin, Inc.6$113
Antares Pharma, Inc.7$113
Companion Medical, Inc.7$111
Clarus Therapeutics Inc.6$101
Lifescan, Inc.5$88
Amneal Pharmaceuticals LLC5$83
Takeda Pharmaceuticals U.S.A., Inc.5$78
Recordati_rare_diseases_inc.4$74
Regeneron Healthcare Solutions, Inc.5$70
Nestle Healthcare Nutrition Inc.3$66
Amphastar Pharmaceuticals, Inc.4$63
Amryt Pharma Holdings Ltd3$59
Verity Pharmaceuticals Inc.3$53
Ipsen Biopharmaceuticals, Inc3$49
Madrigal Pharmaceuticals2$47
Nevro Corp.2$46
Rhythm Pharmaceuticals, Inc.3$45
Amarin Pharma, Inc.3$43
Tolmar, Inc.3$42
Astellas Pharma US Inc2$39
Senseonics, Incorporated2$26
Halozyme Inc1$16
Sanofi US Services Inc.1$15
Bigfoot Biomedical Inc1$14
Eisai Inc.1$14

How this compares

$26,024 in reported general payments places this provider in the 70th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

See all endocrinology, diabetes & metabolism providers in Tennessee →

Medicare billing

Part B allowed, 2024
$197,112
Medicare patients
374
Services billed
5,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Nashville

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →